SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is a top trending stock, driven by high anticipation for its presentation at the J.P. Morgan Healthcare Conference and the imminent PMDA approval in Japan. The community is buzzing about recent positive clinical data, particularly for pancreatic and skin cancer, which showcases the revolutionary Alpha DaRT technology's potential and is attracting significant institutional interest. This momentum, marked by robust volume and new price levels, underscores investor belief in the company's trajectory within the targeted alpha therapy sector.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is actively trending due to its strategic pivot into the high-growth obesity drug market following a recent acquisition and ongoing pipeline developments, including upcoming vaccine trial readouts. The community is keenly focused on the company's ability to execute on these growth drivers and navigate patent expiration pressures, while its strong dividend yield remains a key discussion point for long-term investors.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing intense investor interest following Saudi FDA approval for its ANKTIVA drug in both bladder and lung cancer, complemented by a reported 700% year-over-year revenue surge. The community is eagerly anticipating a significant short squeeze, fueled by enthusiasm for ANKTIVA's chemotherapy-free approach and its potential to revolutionize cancer treatment as a 

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is trending due to surging institutional interest, marked by significant stablecoin inflows and new ETF filings from major financial players. The community is actively discussing large whale accumulations and Solana's growing role as a high-performance blockchain for various applications. Its expanding ecosystem and unique speed position it as a strong contender in the digital asset space, with anticipation for clearer regulatory frameworks.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is trending amidst significant community excitement fueled by its rumored collaboration with POL and recent integration with ACH, reflecting growing interest in its real-world utility as an OG privacy coin. Investors are actively discussing its potential to experience strong upward momentum, drawing comparisons to recent surges observed in other privacy tokens like Zcash during the broader altcoin season.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending amid escalating speculation that Sanofi is preparing an improved takeover offer after an initial bid was rejected. Community discussion points to the company's confidence in its lead drug, AXPAXLI, and an accelerated NDA pathway as key reasons for seeking a higher valuation, with many anticipating a significant premium ahead of upcoming Phase 3 data. This activity highlights broader interest in long-acting therapies for the wet AMD market.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF ($VTI) is trending as it recently achieved new all-time highs, reflecting broad market strength and investor confidence. The community actively discusses VTI as a 'painfully simple yet effective' core holding for diversified, long-term growth, often comparing its steady performance to more concentrated growth funds. This positive sentiment is underpinned by favorable U.S. growth outlooks and an increasing risk appetite across various market sectors.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Energy and Transportation, Financial Products, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Energy and Transportation segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The Financial Products segment provides financing alternatives to customers and dealers for Caterpillar products and services, as well as financing for power generation facilities. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925 and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is trending as it emerges as a significant beneficiary of the AI infrastructure boom, with widespread discussion focusing on its power generation business experiencing surging demand from data centers. This narrative, amplified by strategic partnerships and acquisitions in mining software, is driving robust stock performance. However, some community members voice concerns about its current valuation and the potential for a market pullback.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is trending due to its strategic expansion through acquisitions, recently adding Dynavax and Blueprint Medicines to bolster its vaccine and immunology pipelines. The community is actively discussing a potential sweetened takeover offer for Ocular Therapeutix, alongside ongoing interest in Sanofi's partnership with Novavax. These moves, coupled with the continued strong performance of key drugs like Dupixent, highlight Sanofi's focus on pipeline growth in critical therapeutic areas.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETR is capturing attention amidst significant housing market catalysts, including developments aimed at lowering mortgage rates and facilitating down payments. The community is buzzing about CEO Vishal Garg's vision for Better's AI-driven Tinman platform, which is projected to accelerate loan volume and drive toward profitability through growing enterprise partnerships. Many anticipate a substantial long-term upside, fueled by optimism for its disruptive technology and potential for a short squeeze given its low float.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Personalis (NASDAQ:PSNL) Sees Unusually-High Trading Volume - Here's Why

Personalis (NASDAQ:PSNL) Sees Unusually-High Trading Volume - Should You Buy...

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option added to its ultrasensitive NeXT...

Personalis (NASDAQ:PSNL) Trading Down 8.6% - What's Next?

Personalis (NASDAQ:PSNL) Stock Price Down 8.6% - Here's What Happened...

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results for the fourth quarter and full...

Personalis (NASDAQ:PSNL) Trading 8.1% Higher - Here's Why

Personalis (NASDAQ:PSNL) Trading 8.1% Higher - Should You Buy...

Personalis (NASDAQ:PSNL) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen lowered Personalis from a "hold" rating to a "sell" rating in a report on Saturday...

Smart Oncology: 5 Stocks Chasing the $317B Prize

Smart Oncology: 5 Stocks Chasing the $317B Prize Smart Oncology: 5 Stocks Chasing the $317B Prize PR Newswire VANCOUVER, BC, Dec. 31, 2025 Issued on behalf of Oncolytics Biotech Inc...

Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL - Get Free Report) have earned an average rating of "Moderate Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. One...

Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of "Moderate Buy" by Brokerages

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the stock, MarketBeat.com reports...

Personalis (NASDAQ:PSNL) Sees Strong Trading Volume - Here's Why

Personalis (NASDAQ:PSNL) Sees Unusually-High Trading Volume - Time to Buy...

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Traders are keenly observing a significant uptick in trading volume, including large block orders and a sudden 20%+ daily price jump.

PSNL
Personalis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PSNL News

PSNLPersonalis Inc